COMMUNIQUÉS West-GlobeNewswire

J-Star Signs Exclusive Distribution Agreement with PSSB
23/02/2026
TAICHUNG CITY, Taiwan, Feb. 23, 2026 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (Nasdaq: YMAT) (“J-Star” or the “Company”), a leading provider of innovative carbon fiber and composite solutions serving diverse [...]
Prenetics Launches IM8 Daily Ultimate Essentials PRO — A Clinical Formula with Two New Flavours
23/02/2026
Up to 733% Greater Potency Across 11 Key Nutrients, Including New Saffron Nootropic and Bioactive Vitamin Forms Two New Flavours — Mango + Passionfruit and Lemon + Orange Same Price for New and Existing Customers Full [...]
AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic Cancer
23/02/2026
OCALA, Fla., Feb. 23, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced milestones in the expected timeline for the ongoing Phase 2 clinical study evaluating AIM’ [...]
Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board
23/02/2026
Dr. Anczukow is a leading cancer biologist with expertise in RNA biology, molecular and cell biology, as well as human genetics, cancer biology, and genomics TAMPA, Fla. and LONDON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- [...]
Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026
23/02/2026
Phase 1b translational data demonstrate localized ileocolonic target engagement, suppression of inflammatory and fibrotic gene programs, and early clinical response within seven days Encouraging safety profile across 89 [...]
Blue Genes Partners with RxSense to Deliver Actionable PGx at the Point of Adjudication
23/02/2026
The new partnership will enhance pharmacy benefit decision-making by embedding real-time genetic intelligence into adjudication workflows SCOTTSDALE, Ariz., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Blue Genes today announced a [...]
ICU Medical to Participate in Upcoming Investor Conferences
23/02/2026
SAN CLEMENTE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced its participation in the [...]
Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One
23/02/2026
Regulatory Shift Could Significantly Lower Phase 3 Costs and Accelerate Path Toward NDA Submission for AD04 GLEN ALLEN, Va., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. ( NASDAQ: ADIL ) (“Adial” or the [...]
Bicara Therapeutics to Participate in Upcoming Investor Conferences
23/02/2026
BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]
PharmAla To Supply Amsterdam UMC with LaNeo™ MDMA, Including Development of New Single-Capsule Stability Data
23/02/2026
TORONTO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) , a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives [...]
Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
23/02/2026
MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cyprium entered into a [...]
Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
23/02/2026
PDUFA action date set for August 23, 2026 If approved, DTX401 will be the first treatment to address the underlying cause of GDSIa NOVATO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ [...]
BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman
23/02/2026
Enhanced board oversight aligns subsidiary with disciplined capital allocation and strategic evaluation framework KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“ [...]
rYojbaba Announces Participation in the Guardian Girls Aikido Project in Los Angeles, CA
23/02/2026
FUKUOKA, Japan, Feb. 23, 2026 (GLOBE NEWSWIRE) -- rYojbaba Co., Ltd. (Nasdaq: RYOJ) ("rYojbaba" or the "Company") , a Japanese consulting and health services company, collaborated with Guardian Girls USA and United [...]
FibroBiologics Granted Extension by Nasdaq to Regain Compliance
23/02/2026
HOUSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the [...]
Sutro Biopharma Announces Participation at the 16th World ADC London Summit
23/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug [...]
Milestone Scientific Launches CompuFlo® Advisor Program to Accelerate Commercial Adoption and Drive Utilization Growth in Select MAC Jurisdictions; Plans National Expansion
23/02/2026
ROSELAND, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS) , a leading developer of computerized drug delivery instruments that provide objective, pressure-guided precision, today announced [...]
Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
23/02/2026
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, [...]
Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders
23/02/2026
Multiple new federal actions highlight deep brain neurostimulation as a high-priority emerging therapy for TBI, PTSD, stroke recovery, and Alzheimer’s disease HOUSTON, TX, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Nexalin [...]

Pages